Clearside Biomedical, Inc. – NASDAQ:CLSD
Clearside Biomedical stock price today
$0.407
-0.54
-57.13%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Clearside Biomedical stock price monthly change
-24.00%
month
Clearside Biomedical stock price quarterly change
-24.00%
quarter
Clearside Biomedical stock price yearly change
-19.49%
year
Clearside Biomedical key metrics
Market Cap | 66.43M |
Enterprise value | 27.68M |
P/E | -1.94 |
EV/Sales | 27.76 |
EV/EBITDA | -939.51 |
Price/Sales | 74.87 |
Price/Book | 7.03 |
PEG ratio | 0.01 |
EPS | -0.54 |
Revenue | 8.45M |
EBITDA | -24.92M |
Income | -34.96M |
Revenue Q/Q | 5650% |
Revenue Y/Y | 758.94% |
Profit margin | -3.3% |
Oper. margin | -3.04% |
Gross margin | -38.54% |
EBIT margin | -3.04% |
EBITDA margin | -294.91% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeClearside Biomedical stock price history
Clearside Biomedical stock forecast
Clearside Biomedical financial statements
| Jun 2023 | 1.01M | -9.10M | -894.5% |
|---|---|---|---|
| Sep 2023 | 859K | -9.26M | -1078.81% |
| Dec 2023 | 6.34M | -4.83M | -76.15% |
| Mar 2024 | 230K | -11.76M | -5114.35% |
| Mar 2024 | 230K | -11.76M | -5114.35% |
|---|---|---|---|
| Sep 2025 | 13.06M | -11.23M | -85.95% |
| Oct 2025 | 100K | -10.71M | -10710.59% |
| Dec 2025 | 100K | -12.80M | -12806.19% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 39185000 | 44.15M | 112.69% |
|---|---|---|---|
| Sep 2023 | 34420000 | 47.26M | 137.33% |
| Dec 2023 | 34018000 | 49.93M | 146.78% |
| Mar 2024 | 40142000 | 61.95M | 154.33% |
| Jun 2023 | -5.33M | -1.09M | 22K |
|---|---|---|---|
| Sep 2023 | -6.07M | -445K | 317K |
| Dec 2023 | 495K | -120K | -257K |
| Mar 2024 | -7.85M | -57K | 14.34M |
Clearside Biomedical alternative data
| Aug 2023 | 36 |
|---|---|
| Sep 2023 | 36 |
| Oct 2023 | 36 |
| Nov 2023 | 36 |
| Dec 2023 | 36 |
| Jan 2024 | 36 |
| Feb 2024 | 36 |
| Mar 2024 | 30 |
| Apr 2024 | 30 |
| May 2024 | 30 |
| Jun 2024 | 30 |
| Jul 2024 | 30 |
Clearside Biomedical other data
7.90%
-7.27%
of CLSD is owned by hedge funds
31
-21
4.75M
-4.37M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 10000 | 0 |
| Oct 2023 | 81412 | 0 |
| Nov 2023 | 64366 | 0 |
| Jan 2024 | 0 | 30900 |
| Feb 2024 | 888888 | 0 |
| Mar 2024 | 30000 | 0 |
| Apr 2024 | 100000 | 0 |
| May 2024 | 7813 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | YERXA BENJAMIN R director | Common Stock | 7,813 | $1.31 | $10,235 | ||
Purchase | GIBNEY ANTHONY S director | Common Stock | 93,290 | $1.3 | $121,277 | ||
Purchase | GIBNEY ANTHONY S director | Common Stock | 6,710 | $1.25 | $8,388 | ||
Purchase | CHONG NGAI HANG VICTOR officer: CHIEF MEDICAL OFFICER | Common Stock | 30,000 | $1.6 | $48,000 | ||
Purchase | WHITMORE BRADFORD T 10 percent owner | Common Stock | 444,444 | $1.35 | $599,999 | ||
Purchase | WHITMORE BRADFORD T 10 percent owner | Warrant | 444,444 | $1.62 | $719,999 | ||
Sale | LASEZKAY GEORGE M director, officer: CEO | Common Stock | 18,000 | $1.27 | $22,860 | ||
Sale | DEIGNAN CHARLES A. officer: Chief Fi.. | Common Stock | 12,900 | $1.28 | $16,512 | ||
Purchase | WHITMORE BRADFORD T 10 percent owner | Common Stock | 64,366 | $0.74 | $47,888 | ||
Purchase | WHITMORE BRADFORD T 10 percent owner | Common Stock | 70,812 | $0.73 | $51,551 |
| Patent |
|---|
Application Filling date: 17 Sep 2021 Issue date: 11 Aug 2022 |
Application Filling date: 16 Apr 2020 Issue date: 7 Jul 2022 |
Application Filling date: 10 Nov 2021 Issue date: 3 Mar 2022 |
Application Filling date: 22 Mar 2021 Issue date: 3 Mar 2022 |
Application Filling date: 24 May 2021 Issue date: 25 Nov 2021 |
Application Filling date: 7 May 2021 Issue date: 26 Aug 2021 |
Application Filling date: 6 Apr 2021 Issue date: 22 Jul 2021 |
Application Filling date: 30 Mar 2021 Issue date: 15 Jul 2021 |
Grant Filling date: 11 Aug 2017 Issue date: 13 Apr 2021 |
Grant Utility: Device for ocular access Filling date: 16 Jan 2018 Issue date: 23 Mar 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 13 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D. (1952) Pres, Chief Executive Officer & Director | $681,670 |
| Mr. Charles A. Deignan (1964) Chief Financial Officer | $430,330 |
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio
Clearside Biomedical: A Pivotal 2022 Ahead
Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Clearside's Value Proposition Is Far From Clear
Regenxbio: Suprachoroidal Data May Impress
scPharmaceuticals: The Third Time's A Charm
-
What's the price of Clearside Biomedical stock today?
One share of Clearside Biomedical stock can currently be purchased for approximately $0.41.
-
When is Clearside Biomedical's next earnings date?
Unfortunately, Clearside Biomedical's (CLSD) next earnings date is currently unknown.
-
Does Clearside Biomedical pay dividends?
No, Clearside Biomedical does not pay dividends.
-
How much money does Clearside Biomedical make?
Clearside Biomedical has a market capitalization of 66.43M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 519.89% to 8.23M US dollars.
-
What is Clearside Biomedical's stock symbol?
Clearside Biomedical, Inc. is traded on the NASDAQ under the ticker symbol "CLSD".
-
What is Clearside Biomedical's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Clearside Biomedical?
Shares of Clearside Biomedical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the following people:
- Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D. Pres, Chief Executive Officer & Director(age: 73, pay: $681,670)
- Mr. Charles A. Deignan Chief Financial Officer(age: 61, pay: $430,330)
-
How many employees does Clearside Biomedical have?
As Jul 2024, Clearside Biomedical employs 30 workers.
-
When Clearside Biomedical went public?
Clearside Biomedical, Inc. is publicly traded company for more then 9 years since IPO on 2 Jun 2016.
-
What is Clearside Biomedical's official website?
The official website for Clearside Biomedical is clearsidebio.com.
-
Where are Clearside Biomedical's headquarters?
Clearside Biomedical is headquartered at 900 North Point Parkway, Alpharetta, GA.
-
How can i contact Clearside Biomedical?
Clearside Biomedical's mailing address is 900 North Point Parkway, Alpharetta, GA and company can be reached via phone at +678 2703631.
Clearside Biomedical company profile:
Clearside Biomedical, Inc.
clearsidebio.comExchange:
NASDAQ
Full time employees:
30
Industry:
Biotechnology
Sector:
Healthcare
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
900 North Point Parkway
Alpharetta, GA 30005
Alpharetta, GA 30005
CIK: 0001539029
ISIN: US1850631045
CUSIP: 185063104
